Which COVID-19 vaccine should I get?

Should I try and get an mRNA vaccine? They are better than the others, aren’t they? If I show up at the clinic can I choose?

 These are some of the questions that we didn’t even know we would be so lucky to ask just three months ago. 

The speed at which multiple vaccines to choose from has come about is unprecedented. 

The first genome sequence of a previously unknown virus was published in early January 2020 and the Pfizer and Moderna mRNA vaccines, tested over the summer and fall of 2020, were approved for emergency use in early December. 

These are the quickest vaccines ever developed. Their very speed has raised a lot of questions around their safety. It is true that all previous vaccines have taken years to develop and the cumulative experience of their use over time is reassuring. 

Moderate reactions

Nevertheless the COVID-19 vaccines have been tested in very big trials. As a comparison, the widely used and “uncontroversial” Shingrix vaccine for prevention of shingles was tested in 32,000 participants prior to submission for approval in 2017. The total number of patients in COVID-19 vaccine trials that have reported results so far is 170,000 and growing rapidly. 

The safety results have been reassuring — both in the trial participants and now in millions of people worldwide who have been vaccinated and reported to national monitoring systems. 

Rates of severe side effects, mainly anaphylaxis, have been very rare — a handful in every million vaccinated — and the more common reactions such as arm pain, fever, fatigue and muscle aches have been over very quickly. 

The brief discomfort of COVID-19 vaccines seems to be greater than for the annual flu shot. This probably reflects a combination of both the “prime-boost” two-shot strategy to provoke maximum stimulation of the immune system; and the large group of vaccinees who were recently infected naturally with SARS-CoV-2 and already have a naturally primed immune system ready to react. Maybe the single-shot Johnson & Johnson vaccine will have fewer reactions?

Don’t compare the numbers

There are now three vaccines available in the USA (Pfizer, Moderna and Johnson & Johnson) and several more globally, with more to come. 

Inevitable comparisons between the different vaccines, using their “headline” efficacy numbers, is a favorite media story at the moment. This has stimulated “vaccine shopping,” which has reached damaging levels in places like Germany, where the UK Astra-Zeneca vaccine sits un-used in warehouses whilst people wait, unprotected, for the Pfizer vaccine. 

The efficacy numbers attached to the two shots is responsible for this: 95% for Pfizer versus 62% for Astra-Zeneca. 

These numbers are a snapshot in time and can’t be compared with each other. 

Different vaccine trials

The Pfizer number was generated from a trial mainly in the USA, where most of the patients were recruited in the summer and fall of 2020. 

The Astra-Zeneca number was reported from a trial that included a substantial mixture of patients from the UK, South Africa and Brazil. 

The Pfizer and Moderna trials closely adhered to the three- or four-week interval between doses, whereas the Astra-Zeneca trial had a less strict timing. 

The different trials measured infection and symptoms in different ways at different time points. 

In more recent trials — for example the Johnson & Johnson and Novavax trials — there were large numbers of infections with new virus variants included as well. 

The efficacy result of each trial is reflective of the performance of the vaccine WITHIN that trial compared with a placebo — but not comparable OUTSIDE of the trial with the other vaccines.

Real-world results

To emphasize this, we have recent large-scale program results from the Scottish National Health Service. 

The Astra-Zeneca vaccine has been 94% effective in reducing hospitalizations so far compared with the Pfizer vaccine, which has been 85% effective. 

This reversal of efficacy rankings in a real-world observation simply emphasizes that both vaccines are great. 

The most important number of all to remember is that in the thousands and thousands of trial participants who received any of the vaccines there were no COVID deaths and almost no hospitalizations for COVID.

So when you have finally managed to find your vaccine appointment after refreshing the sign-up page a hundred times and been booked four weeks hence, don’t worry about which vaccine you will get. Just pick the one with the smallest needle.

 

James Shepherd, MD PhD, lives in Sharon and is an Infectious Disease physician and epidemiologist who is on the faculty of the Yale University School of Medicine.

Latest News

P&Z deliberates on Wake Robin expansion
Wake Robin Inn is located on Sharon Road in Lakeville.
Photo by John Coston

LAKEVILLE — Nearly a month after closing the public hearing on the proposed Wake Robin Inn redevelopment, the Planning and Zoning Commission began its deliberations last week over the course of two special meetings devoted solely to the controversial project.

Over four hours of discussion helped the Commission to establish its position at this stage in the process, about a month before its statutory window to render a decision expires on Nov. 13.

Keep ReadingShow less
Fallen tree cancels jubilee

The roof of the Grove was damaged by the tree, the event tent was punctured, a chef was injured and the Jubilee Luncheon was canceled Sunday, Oct. 12.

Photo by Patrick L. Sullivan

LAKEVILLE — The Lakeville Journal and The Millerton News Jubilee Luncheon fundraiser at the Grove Sunday, Oct. 12 was canceled after a very large section of a tree fell on the caterer’s tent at about 10 a.m.

Most of the catering staff heard the tree breaking up and got out of the tent in time, but the chef was hit by the falling limbs and sustained non-critical injuries.

Keep ReadingShow less
Kent School senior killed, parents hurt in car crash

Emergency responders block Amenia Union Road in Sharon Saturday, Oct. 11, while responding to the vehicle crash.

Photo by Patrick L. Sullivan

Updated Oct. 13, 9:25 a.m.:

SHARON — Shea Cassidy-Teti, 17, of Salisbury, died Saturday, Oct. 11, in a tragic car crash on Amenia Union Road in Sharon.

Keep ReadingShow less
Rhys V. Bowen

LAKEVILLE — Rhys V. Bowen, 65, of Foxboro, Massachusetts, died unexpectedly in his sleep on Sept. 15, 2025. Rhys was born in Sharon, Connecticut, on April 9, 1960 to Anne H. Bowen and the late John G. Bowen. His brother, David, died in 1979.

Rhys grew up at The Hotchkiss School in Lakeville, where his father taught English. Attending Hotchkiss, Rhys excelled in academics and played soccer, basketball, and baseball. During these years, he also learned the challenges and joys of running, and continued to run at least 50 miles a week, until the day he died.

Keep ReadingShow less